Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, Changing Treatment Landscape in Bladder Cancer, at the BTIG Virtual Biotechnology Conference.

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer